GRCE
Grace Therapeutics, Inc.
Biotechnology
Market Cap$37M
5Y Perf.-25.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
GRCE vs ACAD
Revenue, margins, valuation, and 5-year total return — side by side.
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.68B
5Y Perf.+47.2%
GRCE vs ACAD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | GRCE | ACAD |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $37M | $3.68B |
| Revenue (TTM) | $0.00 | $1.07B |
| Net Income (TTM) | $-6M | $391M |
| Gross Margin | — | 91.7% |
| Operating Margin | — | 9.8% |
| Forward P/E | — | 48.5x |
| Total Debt | $0.00 | $52M |
| Cash & Equiv. | $22M | $178M |
GRCE vs ACAD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GRCE
ACAD
| Stock | Oct 24 | May 26 | Return |
|---|---|---|---|
| Grace Therapeutics,… (GRCE) | 100 | 74.1 | -25.9% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 147.2 | +47.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GRCE vs ACAD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ACAD leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Grace Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
GRCE
Grace Therapeutics, Inc.
The Income Pick
GRCE is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.87
- -21.3% 10Y total return vs ACAD's -22.3%
- Lower volatility, beta 0.87, current ratio 11.77x
Best for: income & stability and long-term compounding
ACAD
ACADIA Pharmaceuticals Inc.
The Growth Play
ACAD carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 11.9%, EPS growth 68.4%, 3Y rev CAGR 27.5%
- 36.5% margin vs GRCE's 1.0%
- +47.7% vs GRCE's -19.7%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | GRCE | 55.3% revenue growth vs ACAD's 11.9% |
| Quality / Margins | ACAD | 36.5% margin vs GRCE's 1.0% |
| Stability / Safety | GRCE | Beta 0.87 vs ACAD's 1.26 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ACAD | +47.7% vs GRCE's -19.7% |
| Efficiency (ROA) | ACAD | 29.8% ROA vs GRCE's -8.7%, ROIC 10.0% vs -30.1% |
GRCE vs ACAD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2018
GRCE vs ACAD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACADLAGGINGGRCE
GRCEGrace Therapeutics, I…
1leads
ACADACADIA Pharmaceutical…
3leads
6 Total Categories
CATEGORYLEADERvs GRCEMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACAD1/1
Valuation MetricsMultiples, price ratios, and targets
GRCE2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACAD6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
ACAD5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACAD leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ACAD and GRCE operate at a comparable scale, with $1.1B and $0 in trailing revenue.
| Metric | GRCEGrace Therapeutic… | ACADACADIA Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $1.1B |
| EBITDAEarnings before interest/tax | -$9M | $123M |
| Net IncomeAfter-tax profit | -$6M | $391M |
| Free Cash FlowCash after capex | -$10M | $105M |
| Gross MarginGross profit ÷ Revenue | — | +91.7% |
| Operating MarginEBIT ÷ Revenue | — | +9.8% |
| Net MarginNet income ÷ Revenue | — | +36.5% |
| FCF MarginFCF ÷ Revenue | — | +9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +9.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +61.1% | +86.0% |
ACAD leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
GRCE leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | GRCEGrace Therapeutic… | ACADACADIA Pharmaceut… |
|---|---|---|
| Market CapShares × price | $37M | $3.7B |
| Enterprise ValueMkt cap + debt − cash | $15M | $3.6B |
| Trailing P/EPrice ÷ TTM EPS | -3.00x | 9.38x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 48.47x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 25.57x |
| Price / SalesMarket cap ÷ Revenue | — | 3.43x |
| Price / BookPrice ÷ Book value/share | 0.43x | 3.00x |
| Price / FCFMarket cap ÷ FCF | — | 34.98x |
GRCE leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ACAD leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
ACAD delivers a 41.9% return on equity — every $100 of shareholder capital generates $42 in annual profit, vs $-9 for GRCE. On the Piotroski fundamental quality scale (0–9), ACAD scores 6/9 vs GRCE's 1/9, reflecting solid financial health.
| Metric | GRCEGrace Therapeutic… | ACADACADIA Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -9.2% | +41.9% |
| ROA (TTM)Return on assets | -8.7% | +29.8% |
| ROICReturn on invested capital | -30.1% | +10.0% |
| ROCEReturn on capital employed | -23.5% | +10.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 6 |
| Debt / EquityFinancial leverage | — | 0.04x |
| Net DebtTotal debt minus cash | -$22M | -$126M |
| Cash & Equiv.Liquid assets | $22M | $178M |
| Total DebtShort + long-term debt | $0 | $52M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
ACAD leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
ACAD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACAD five years ago would be worth $10,253 today (with dividends reinvested), compared to $7,874 for GRCE. Over the past 12 months, ACAD leads with a +47.7% total return vs GRCE's -19.7%. The 3-year compound annual growth rate (CAGR) favors ACAD at -0.1% vs GRCE's -7.7% — a key indicator of consistent wealth creation.
| Metric | GRCEGrace Therapeutic… | ACADACADIA Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -35.2% | -17.9% |
| 1-Year ReturnPast 12 months | -19.7% | +47.7% |
| 3-Year ReturnCumulative with dividends | -21.3% | -0.3% |
| 5-Year ReturnCumulative with dividends | -21.3% | +2.5% |
| 10-Year ReturnCumulative with dividends | -21.3% | -22.3% |
| CAGR (3Y)Annualised 3-year return | -7.7% | -0.1% |
ACAD leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — GRCE and ACAD each lead in 1 of 2 comparable metrics.
Risk & Volatility
GRCE is the less volatile stock with a 0.87 beta — it tends to amplify market swings less than ACAD's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACAD currently trades 77.2% from its 52-week high vs GRCE's 45.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GRCEGrace Therapeutic… | ACADACADIA Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.87x | 1.26x |
| 52-Week HighHighest price in past year | $5.18 | $27.81 |
| 52-Week LowLowest price in past year | $1.79 | $14.45 |
| % of 52W HighCurrent price vs 52-week peak | +45.8% | +77.2% |
| RSI (14)Momentum oscillator 0–100 | 32.2 | 52.3 |
| Avg Volume (50D)Average daily shares traded | 881K | 1.7M |
Evenly matched — GRCE and ACAD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | GRCEGrace Therapeutic… | ACADACADIA Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $34.78 |
| # AnalystsCovering analysts | — | 37 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). GRCE leads in 1 (Valuation Metrics). 1 tied.
Best OverallACADIA Pharmaceuticals Inc. (ACAD)Leads 3 of 6 categories
Loading custom metrics...
GRCE vs ACAD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is GRCE or ACAD a better buy right now?
ACADIA Pharmaceuticals Inc.
(ACAD) offers the better valuation at 9. 4x trailing P/E (48. 5x forward), making it the more compelling value choice. Analysts rate ACADIA Pharmaceuticals Inc. (ACAD) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — GRCE or ACAD?
Over the past 5 years, ACADIA Pharmaceuticals Inc.
(ACAD) delivered a total return of +2. 5%, compared to -21. 3% for Grace Therapeutics, Inc. (GRCE). Over 10 years, the gap is even starker: GRCE returned -21. 3% versus ACAD's -22. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — GRCE or ACAD?
By beta (market sensitivity over 5 years), Grace Therapeutics, Inc.
(GRCE) is the lower-risk stock at 0. 87β versus ACADIA Pharmaceuticals Inc. 's 1. 26β — meaning ACAD is approximately 45% more volatile than GRCE relative to the S&P 500.
04Which is growing faster — GRCE or ACAD?
On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc.
grew EPS 68. 4% year-over-year, compared to 54. 3% for Grace Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — GRCE or ACAD?
ACADIA Pharmaceuticals Inc.
(ACAD) is the more profitable company, earning 36. 5% net margin versus 0. 0% for Grace Therapeutics, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus 0. 0% for GRCE. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — GRCE or ACAD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is GRCE or ACAD better for a retirement portfolio?
For long-horizon retirement investors, Grace Therapeutics, Inc.
(GRCE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87)). Both have compounded well over 10 years (GRCE: -21. 3%, ACAD: -22. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between GRCE and ACAD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: GRCE is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.